RIGI and neoplasm: RIG-I plays a key role in immunotherapy [14,15]; the activation of RIG-I by the targeted nanoparticle delivery of agonists is the key to generating an immune response, thereby inducing tumor cell killing and enhancing the therapeutic effect [16,17,18,19].